Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Open Access
- 1 May 1996
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 55 (5) , 288-293
- https://doi.org/10.1136/ard.55.5.288
Abstract
OBJECTIVE: To examine the effect of high dose corticosteroid pulse treatment (three times 200 mg dexamethasone intravenously in eight days) on calcium and bone metabolism in 17 consecutive patients with active rheumatoid arthritis (RA). METHODS: Bone formation was quantified by measurement of serum alkaline phosphatase, osteocalcin, and carboxyterminal propeptide of type I procollagen (pro-I-CPP) concentrations. Bone resorption was measured by urinary excretion of calcium, hydroxyproline, (free and total) deoxypyridinoline (Dpyr), (free and total) pyridinoline (Pyr), and serum concentrations of the carboxyterminal cross linked telopeptide of type I collagen (I-CTP). Disease activity of RA was measured by erythrocyte sedimentation rate, C reactive protein, and Ritchie and Thompson joint scores. RESULTS: Disease activity was initially high, and decreased during corticosteroid pulse treatment and the following five weeks. Osteocalcin, alkaline phosphatase, and pro-I-CPP concentrations were initially within normal limits, while I-CTP, Dpyr, and Pyr were increased. Osteocalcin and pro-I-CPP concentrations decreased (p < 0.01) during corticosteroid pulse treatment, but rapidly returned to baseline after the treatment. No changes were observed in alkaline phosphatase and urinary excretion of calcium and hydroxyproline. Bone resorption measured by serum I-CTP and urinary excretion of Pyr and Dpyr was unchanged or decreased (p < 0.05-0.01), depending on the time of measurement and the parameter measured. CONCLUSIONS: In these patients with active RA, bone resorption was increased, while bone formation was within normal limits. During high dose corticosteroid pulse treatment, bone formation was only transiently decreased, while markers of bone resorption were unchanged or decreased. Because corticosteroid pulse treatment has only a short term negative effect on bone formation, and because it probably reduces bone resorption, at least partly as a result of the decreased disease activity, the effect of corticosteroid pulse treatment on bone may be assumed to be relatively mild.Keywords
This publication has 35 references indexed in Scilit:
- URINARY HYDROXYPYRIDINIUM CROSS-LINKS OF COLLAGEN IN RHEUMATOID ARTHRITIS. RELATION TO DISEASE ACTIVITY AND EFFECTS OF METHYLPREDNISOLONERheumatology, 1994
- TRANSIENT DECREASE IN OSTEOCALCIN AND MARKERS OF TYPE 1 COLLAGEN TURNOVER DURING HIGH-DOSE CORTICOSTEROID PULSE THERAPY IN RHEUMATOID ARTHRITISRheumatology, 1993
- Measuring collagen degradationEuropean Journal of Clinical Investigation, 1993
- Immunoassay of pyridinoline crosslink excretion in normal adults and in paget's diseaseJournal of Bone and Mineral Research, 1993
- BONE METABOLISM IN RHEUMATOID ARTHRITIS; RELATION TO DISEASE ACTIVITYRheumatology, 1993
- Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assayJournal of Bone and Mineral Research, 1992
- URINARY COLLAGEN CROSSLINKS REFLECT THE RADIOGRAPHIC SEVERITY OF KNEE OSTEOARTHRITISRheumatology, 1992
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1986
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983